A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

被引：98

作者：

Bernardes, Goncalo J. L. ^{[1
]}

Casi, Giulio ^{[2
]}

Truessel, Sabrina ^{[1
]}

Hartmann, Isabelle ^{[1
]}

Schwager, Kathrin ^{[1
,2
]}

Scheuermann, Joerg

Neri, Dario ^{[1
]}

机构：

[1] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland

[2] Philochem AG, CH-8112 Otelfingen, Switzerland

来源：

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | 2012年 / 51卷 / 04期

基金：

瑞士国家科学基金会;

关键词：

angiogenesis; antibody-drug conjugates; cancer; cemadotin; drug delivery; ANTINEOPLASTIC AGENTS; TUMORS; FIBRONECTIN; DOMAIN; EXPRESSION;

D O I：

10.1002/anie.201106527

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Right on target: A chemically defined vascular-targeting antibody-drug conjugate (ADC) that offers comprehensive tumor coverage has been developed. When injected intravenously, this ADC potently inhibited tumor growth in a syngeneic immunocompetent model of murine cancer which cannot be cured by conventional cytotoxic agents. Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

引用

页码：941 / 944

页数：4

共 30 条

[1] Site-Specific and Stoichiometric Conjugation of Cationic Porphyrins to Antiangiogenic Monoclonal Antibodies [J].

Alonso, Cristina M. A. ;

Palumbo, Alessandro ;

Bullous, Aaron J. ;

Pretto, Francesca ;

Neri, Dario ;

Boyle, Ross W. .

BIOCONJUGATE CHEMISTRY, 2010, 21 (02) :302-313

[2] Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: Identification of the best-suited radioimmunoconjugate [J].

Berndorff, D ;

Borkowski, S ;

Sieger, S ;

Rother, A ;

Friebe, M ;

Viti, F ;

Hilger, CS ;

Cyr, JE ;

Dinkelborg, LM .

CLINICAL CANCER RESEARCH, 2005, 11 (19) :7053S-7063S

[3] Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin [J].

Borsi, L ;

Balza, E ;

Bestagno, M ;

Castellani, P ;

Carnemolla, B ;

Biro, A ;

Leprini, A ;

Sepulveda, J ;

Burrone, O ;

Neri, D ;

Zardi, L .

INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (01) :75-85

[4] Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy [J].

Burris, Howard A., III ;

Rugo, Hope S. ;

Vukelja, Svetislava J. ;

Vogel, Charles L. ;

Borson, Rachel A. ;

Limentani, Steven ;

Tan-Chiu, Elizabeth ;

Krop, Ian E. ;

Michaelson, Richard A. ;

Girish, Sandhya ;

Amler, Lukas ;

Zheng, Maoxia ;

Chu, Yu-Waye ;

Klencke, Barbara ;

O'Shaughnessy, Joyce A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :398-405

[5] Potent antibody therapeutics by design [J].

Carter, PJ .

NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :343-357

[6] A "Tag-and-Modify" Approach to Site-Selective Protein Modification [J].

Chalker, Justin M. ;

Bernardes, Goncalo J. L. ;

Davis, Benjamin G. .

ACCOUNTS OF CHEMICAL RESEARCH, 2011, 44 (09) :730-741

[7] Chemical Modification of Proteins at Cysteine: Opportunities in Chemistry and Biology [J].

Chalker, Justin M. ;

Bernardes, Goncalo J. L. ;

Lin, Yuya A. ;

Davis, Benjamin G. .

CHEMISTRY-AN ASIAN JOURNAL, 2009, 4 (05) :630-640

[8] Targeted cancer therapy: Conferring specificity to cytotoxic drugs [J].

Chari, Ravi V. J. .

ACCOUNTS OF CHEMICAL RESEARCH, 2008, 41 (01) :98-107

[9]

DEARRUDA M, 1995, CANCER RES, V55, P3085

[10] Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent [J].

Dennis, Mark S. ;

Jin, Hongkui ;

Dugger, Debra ;

Yang, Renhui ;

McFarland, Leanne ;

Ogasawara, Annie ;

Williams, Simon ;

Cole, Mary J. ;

Ross, Sarajane ;

Schwall, Ralph .

CANCER RESEARCH, 2007, 67 (01) :254-261

← 1 2 3 →